Nogapendekin alfa inbakicept
- Generic Name
- Nogapendekin alfa inbakicept
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
Phase 1
Withdrawn
- Conditions
- Urothelial Carcinoma
- Interventions
- Drug: 5Fluorouracil (5-FU)Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03197571
QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
Phase 1
Withdrawn
- Conditions
- Ovarian Cancer
- Interventions
- Radiation: Stereotactic Body Radiation TherapyBiological: haNK®
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03197584
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
Phase 1
Withdrawn
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03175666
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
Phase 1
Withdrawn
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169764
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
Phase 1
Withdrawn
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169790
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
Phase 1
Withdrawn
- Conditions
- Colorectal Cancer
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169777
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
Phase 1
Withdrawn
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169738
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
Phase 1
Withdrawn
- Conditions
- Melanoma
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03167177
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
Phase 1
Withdrawn
- Conditions
- Merkel Cell Carcinoma
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03167164
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 190
- Registration Number
- NCT03022825
- Locations
- 🇺🇸
Integrated Medical Professionals, New York, New York, United States
🇺🇸Alaska Clinical Research Center, Anchorage, Alaska, United States
🇺🇸Arkansas Urology, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath